Skip to content
Vivo logo
← All articles

Clinicians: 5 Checks Before Accepting 503A vs 503B Shipments

Clinicians: 5 Checks Before Accepting 503A vs 503B Shipments

Two geometric routes converge at a checkpoint

503A pharmacies compound patient-specific prescriptions under state oversight; 503B outsourcing facilities are FDA-registered, cGMP facilities able to make batches for office use and are subject to scheduled FDA inspections. For clinicians and informed consumers sourcing compounded medications, that distinction drives nearly every procurement decision: who inspects the facility, what documentation exists, and whether a clinic can legally stock product ahead of a prescription.

TL;DR:

  • Check the FDA’s public outsourcing facility table for 503B inspection history and recalls; a Form FDA 483 records deviations but is not an enforcement action.
  • Choose 503A for a nonstandard strength, flavor, or delivery route prescribed for one patient; clinics needing stock for multiple patients should consider 503B instead.
  • Verify facility status with the FDA or state board, request each lot’s COA, and check labels for its name, lot number, and beyond use date.
  • Neither category guarantees safety: compounded drugs lack FDA premarket approval, so assess supplier records and pause orders when Form FDA 483 findings remain unresolved.
Vivo ClinicExplore Provider-Supervised CareVivo Clinic offers provider-supervised therapies prepared by licensed U.S. pharmacies, with personalized treatment selection and HIPAA-compliant data practices.Explore treatment options

Table of Contents

What is a 503A compounding pharmacy?

A 503A compounding pharmacy operates under state board of pharmacy oversight and compounds medications only against a valid, patient-specific prescription. This structure suits individualized dosing, such as adjusting a strength or removing an allergen for a single patient, but it limits how much product a facility can prepare in advance and restricts distribution to that named patient.

Quality practices at 503A pharmacies are typically guided by USP compounding chapters rather than federal manufacturing rules:

  • USP <795> governs nonsterile compounding procedures and documentation.
  • USP <797> sets sterility standards for injectable and other sterile preparations.
  • USP <800> addresses handling of hazardous drugs.

Clinicians should expect a beyond-use date (BUD) on every label, along with lot-specific records, though the depth of documentation varies by pharmacy since there is no single federal inspection standard applied uniformly across states.

What is a 503B outsourcing facility?

A 503B outsourcing facility registers voluntarily with the FDA and operates under current good manufacturing practice (cGMP) rules found in 21 CFR Parts 210 and 211. That federal registration is what allows a 503B facility to prepare larger batches for office use, meaning a clinic can stock inventory before a specific patient is identified, something a 503A pharmacy cannot do.

Key operational traits of 503B facilities include:

  • FDA risk-based inspections rather than state-only oversight.
  • Legal ability to ship compounded products across state lines for clinic inventory.
  • Mandatory adverse event reporting to FDA.
  • Labeling requirements that identify the facility as an outsourcing facility under section 503B.

This combination of scale and federal accountability is why many clinics rely on 503B suppliers for higher-volume or multi-patient protocols.

Direct regulatory and quality comparison you can act on

The clearest way to separate these two pathways is by asking who inspects the facility and what the inspection record actually shows. 503B facilities appear in a public FDA table that lists registration status and inspection history, updated on a regular schedule. 503A pharmacies, by contrast, are overseen primarily by state boards of pharmacy, and the FDA typically becomes involved only through for-cause inspections tied to a specific complaint or adverse event, according to Brookings’ comparison of FDA oversight.

A 503B facility’s inspection history, including Form FDA 483 observations and recall records, is searchable in FDA’s public outsourcing facility table, giving clinicians a verification step that simply does not exist for most 503A pharmacies.

The statutory basis also differs. Sections 503A and 503B of the FD&C Act specify different exemptions: 503B compounds may be exempt from certain FD&C Act provisions, including sections tied to new drug approval and track-and-trace requirements, when conditions around cGMP and reporting are met. 503A compounds follow a narrower exemption scope tied directly to the patient-specific prescription requirement. A Form FDA 483 issued to a 503B facility lists observed deviations from cGMP; it is not automatically a recall or an enforcement action, but it signals areas a buyer should ask about directly before placing an order.

When to order from 503A versus 503B

The practical choice usually comes down to volume and specificity rather than a blanket preference for one pathway:

  1. Choose a 503A pharmacy when a patient needs an individualized formulation, such as a nonstandard strength, flavor, or delivery route tied to one prescription.
  2. Choose a 503B outsourcing facility when a clinic needs ready-to-use inventory for multiple patients without waiting on prescription-by-prescription compounding.
  3. Confirm shipping terms before ordering: 503B facilities can generally ship across state lines for office use, while 503A pharmacies face more restrictions tied to patient-specific dispensing.
  4. Align storage and BUD tracking with whichever labeling system the supplier uses, since practices are not standardized across all facilities.

Pro Tip: Request a recent inspection summary or Form FDA 483 response before adding a new 503B vendor to a standing order, not just at initial onboarding.

How to verify a compounder’s status and required documents

Before accepting a shipment, confirm the facility’s actual regulatory category rather than assuming it from marketing language:

  • Search the FDA outsourcing facility table by name to confirm active 503B registration and review recent inspection entries.
  • Check the relevant state board of pharmacy license database to confirm 503A status and current licensure.
  • Request a Certificate of Analysis (COA) for the specific lot, along with sterility and potency test results where applicable.
  • Ask for the BUD, lot number, and the full legal name of the compounding facility printed on the label.
  • Treat a refusal to name the compounding facility, or a label with no lot number, as a reason to decline the order.

A 503B entity can register as an outsourcing facility without separately holding a pharmacy license, so confirming facility type, not just a name on a label, is part of basic due diligence.

Risks, quality assurance, and red flags

Neither pathway produces an FDA-approved drug. Compounded medications are exempt from premarket approval under specific statutory conditions, which means the FDA does not verify safety, effectiveness, or quality before a compounded product reaches a patient, regardless of whether it came from a 503A pharmacy or a 503B facility.

Registered 503B facilities are listed in FDA’s public inspection table, and that same table can show compliance problems, not just clean records, including warning letters like the one issued to RC Outsourcing LLC, which illustrates that registration alone does not guarantee an absence of cGMP nonconformance. Request supplier qualification records and recent COAs, and treat a pattern of unresolved Form FDA 483 observations as grounds to pause an order rather than assume routine compliance.

How we source compounded therapies

We work only with licensed U.S. compounding pharmacies and request a Certificate of Analysis for each lot before a therapy reaches a patient. Our sourcing documentation includes:

  • The compounding facility’s name and licensure status, confirmed before any product is added to a treatment plan.
  • Sterility and potency testing records tied to specific lot numbers.
  • HIPAA-compliant handling of patient data throughout our telehealth intake and provider-review process.

Every treatment plan we offer, from NAD+ to GLP-1 therapies, passes through licensed provider review before dispensing, consistent with how we describe our sourcing approach to patients.

What the 503A vs 503B debate gets wrong

What the 503A vs 503B debate gets wrong — overview diagram

Most discussions of 503A versus 503B treat registration status as a proxy for safety, as though a 503B stamp settles the question and a 503A pharmacy is automatically less rigorous. That framing misses the point: registration tells you who has jurisdiction to inspect, not whether a specific batch was handled correctly. A well-run 503A pharmacy with tight USP <797> discipline can outperform a 503B facility sitting on unresolved Form FDA 483 findings.

The conventional advice, “ask if it’s 503A or 503B,” is necessary but not sufficient. The more useful question is what documentation exists for the specific lot in front of you: a current COA, a traceable lot number, and a named facility willing to stand behind its inspection history. Readers should prioritize document-level verification over category-level assumptions, because the regulatory label describes a pathway, not a guarantee. For a deeper look at infusion-specific safety signals, including how FDA alerts surface in practice, see this partner analysis of IV hydration safety reports.

— Jack

A telehealth route to provider-supervised compounded therapies

For readers who want provider-supervised compounded therapies without separately vetting individual pharmacies, we offer a telehealth model built around licensed sourcing and documented oversight. Our current lineup includes NAD+ Nasal Spray at $129 per month, Glutathione Nasal Spray at $149 per month, Sermorelin at $139 per month, MIC+B12 at $119 per month, NAD+ Face Cream at $129 per month, and Tirzepatide & Semaglutide at $199 per month.

Each plan is backed by a named compounding pharmacy and a per-lot Certificate of Analysis, giving clinicians and patients the same documentation trail this article recommends requesting from any supplier. Visit our patient portal to review treatment options and start provider intake.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

A telehealth route to provider-supervised compounded therapies — overview diagram

FAQ

Which is safer, 503A or 503B pharmacy?

Neither pathway is inherently safer in every case, since both involve compounded drugs that the FDA does not approve before they reach a patient. Safety depends on the specific facility’s documentation, inspection history, and quality practices rather than on the regulatory category alone.

Are 503A pharmacies still able to compound tirzepatide?

503A pharmacies can compound tirzepatide for an individual patient under a valid, patient-specific prescription, subject to state board oversight and standard compounding limitations. Availability and specific formulations can change as FDA guidance and drug shortage determinations evolve, so confirming current status with the pharmacy is advisable.

How do you know if a pharmacy is 503A or 503B?

Check the FDA’s public outsourcing facility table to confirm active 503B registration, since 503A pharmacies do not appear there. For 503A status, verify licensure directly with the relevant state board of pharmacy.

Is 503B or 503A better?

Neither is universally better. 503B suits clinics needing office-use inventory under federal cGMP oversight, while 503A fits individualized, patient-specific formulations under state board oversight.

Sources